Interviews with Pharma and Biotech Global Leaders
Refine Search
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Biotechnology
While much of the world’s focus is on what pharma can do to end the coronavirus pandemic, the rest of the industry is continuing its work ensuring innovative medicines reach those most in need. 17 November 2020
Pharmaceutical
At the annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, Johnson & Johnson’s pharma arm Janssen hopes to raise the bar with quality of life data for Erleada (apalutamide). 17 September 2020
Biotechnology
Insights from Jeevan Virk, UK and Ireland general manager of Advanced Accelerator Applications. 18 August 2020
Pharmaceutical
A collaborative framework in which national and foreign actors converge allows the people of Uruguay access to a wide range of medicines, and the resilience of this structure has been shown during the COVID-19 pandemic, writes The Pharma Letter's Latin American correspondent. 23 July 2020
Pharmaceutical
While vaccine developers including Moderna Therapeutics and AstraZeneca have reported promising results from their COVID-19 programs, the world urgently needs better options for the large number of people being hospitalized with the disease. 17 July 2020
Biotechnology
There was a time when executives at Teva Pharmaceutical Industries thought that their product might be the third anti-calcitonin gene-related peptide (CGRP) drug to be recommended by the National Institute for Health and Care Excellence (NICE). 29 April 2020
Biotechnology
Located at the heart of the Cambridge biotech cluster in Massachusetts, Kymera Therapeutics is exploring the notion that targeted protein degradation could provide a way to treat previously untreatable conditions. 9 March 2020
Pharmaceutical
An interview with Rob DiCicco, deputy chief health officer, IBM Watson Health. 4 March 2020
Pharmaceutical
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken by US biotech Tetra Therapeutics. 17 February 2020
Biotechnology
As biotech companies making themselves eligible to a big pharma buyout go, Imugene appears to tick a lot of the boxes – but the proof of the pudding will come with all important trial results. 24 January 2020
Biosimilars
In partnership with Samsung Bioepis – a joint venture in which it recently upped its stake in to 49.9% - the US biotech company Biogen has been an undisputed leader in driving the adoption of biosimilars in Europe. 2 January 2020
Biosimilars
Biosimilars manufacturers can get a bad rap.
Derided as offering mere "copycats," piggybacking off the success of true innovators, companies such as South Korea's Samsung Bioepis have struggled to break into established markets that favor brand names. 6 December 2019
Biotechnology
Orchard Therapeutics has big ambitions for its role in pioneering some of the most advanced treatments in development today. 25 November 2019
Biotechnology
In March 2019, after a series of political convolutions worthy of a Choose Your Own Adventure novel, former UK Prime Minister Theresa May finally managed to bring her country, and its complaining industries, to the brink of Brexit. 23 October 2019
Pharmaceutical
When the US Food and Drug Administration found that it was in danger of drowning in the volume of safety reports being submitted relating to approved therapies, the agency brought in Transcelerate BioPharma to help. 17 October 2019
Pharmaceutical
In the run-up to the annual meeting of the European Society of Medical Oncology (ESMO), one of the more eagerly anticipated presentations focused on former Loxo Oncology candidate selpercatinib (LOXO-292), a RET inhibitor. 4 October 2019
Pharmaceutical
As the dust settles on 2019’s annual meeting of the European Society of Medical Oncology (ESMO), data from several candidates give hope that the burden of disease may soon be alleviated for millions of people diagnosed with bladder cancer. 4 October 2019
Pharmaceutical
Pivotal data from a Phase II study of the FGFR inhibitor pemigatinib will be used to support a US filing later in the year, says Incyte chief executive Hervé Hoppenot. 27 September 2019
Biotechnology
In Cambridge, USA, just around the corner from fellow gene therapy specialist bluebird bio, a less well-known biotech startup could be about to shake up the market for certain rare disease therapies. 24 September 2019
Biotechnology
Investors in the Atlas Venture-backed immuno-oncology specialist Surface Oncology have had a rough time since the company went public in New York, early in 2018. 5 September 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze